| A clinical trial of a whole-virus H5N1 vaccine derived from cell culture HJ Ehrlich, M Müller, HML Oh, PA Tambyah, C Joukhadar, E Montomoli, ... New England Journal of Medicine 358 (24), 2573-2584, 2008 | 307 | 2008 |
| Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events HJ Ehrlich, MJ Henzl, ED Gomperts Haemophilia 8 (2), 83-90, 2002 | 286 | 2002 |
| Protein Z-dependent regulation of coagulation GJ Broze Jr Thrombosis and haemostasis 86 (07), 08-13, 2001 | 238 | 2001 |
| Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. HJ Ehrlich, RK Gebbink, J Keijer, M Linders, KT Preissner, H Pannekoek Journal of Biological Chemistry 265 (22), 13029-13035, 1990 | 225 | 1990 |
| Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback … C Kost, W Stüber, HJ Ehrlich, H Pannekoek, KT Preissner Journal of Biological Chemistry 267 (17), 12098-12105, 1992 | 181 | 1992 |
| Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies B Plaimauer, JAK Hovinga, C Juno, MJ Wolfsegger, S Skalicky, ... journal of Thrombosis and Haemostasis 9 (5), 936-944, 2011 | 177 | 2011 |
| Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. KT Preissner, J Grulich-Henn, HJ Ehrlich, P Declerck, C Justus, D Collen, ... Journal of Biological Chemistry 265 (30), 18490-18498, 1990 | 154 | 1990 |
| Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin HJ Ehrlich, J Keijer, KT Preissner, RK Gebbink, H Pannekoek Biochemistry 30 (4), 1021-1028, 1991 | 142 | 1991 |
| BAX 855, a PEGylated rFVIII product with prolonged half-life PL Turecek, MJ Bossard, M Graninger, H Gritsch, W Höllriegl, M Kaliwoda, ... Hämostaseologie 32 (S 01), S29-S38, 2012 | 135 | 2012 |
| Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial PN Barrett, G Berezuk, S Fritsch, G Aichinger, MK Hart, W El-Amin, ... The Lancet 377 (9767), 751-759, 2011 | 126 | 2011 |
| History of TBE vaccines PN Barrett, S Schober-Bendixen, HJ Ehrlich Vaccine 21, S41-S49, 2003 | 125 | 2003 |
| The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic … J Keijer, M Linders, AJ van Zonneveld, HJ Ehrlich, JP de Boer, ... | 121 | 1991 |
| On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site J Keijer, M Linders, JJ Wegman, HJ Ehrlich, K Mertens, H Pannekoek | 117 | 1991 |
| A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans KK Orlinger, Y Hofmeister, R Fritz, GW Holzer, FG Falkner, B Unger, ... Journal of Infectious diseases 203 (11), 1556-1564, 2011 | 116 | 2011 |
| Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial N Wressnigg, EM Pöllabauer, G Aichinger, D Portsmouth, A Löw-Baselli, ... The Lancet infectious diseases 13 (8), 680-689, 2013 | 112 | 2013 |
| Structure-function relationships in serpins: current concepts and controversies A Gils, PJ Declerck Thrombosis and haemostasis 80 (10), 531-541, 1998 | 110 | 1998 |
| Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. HJ Ehrlich, RK Gebbink, KT Preissner, J Keijer, NL Esmon, K Mertens, ... The Journal of cell biology 115 (6), 1773-1781, 1991 | 104 | 1991 |
| Glycoproteomic characterization of butyrylcholinesterase from human plasma D Kolarich, A Weber, M Pabst, J Stadlmann, W Teschner, H Ehrlich, ... Proteomics 8 (2), 254-263, 2008 | 100 | 2008 |
| Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin. HJ Ehrlich, RK Gebbink, J Keijer, H Pannekoek Journal of Biological Chemistry 267 (16), 11606-11611, 1992 | 95 | 1992 |
| Prevention of tick-borne encephalitis by FSME-IMMUN® vaccines: review of a clinical development programme A Loew-Baselli, EM Poellabauer, BG Pavlova, S Fritsch, C Firth, ... Vaccine 29 (43), 7307-7319, 2011 | 87 | 2011 |
